{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:18:10Z","timestamp":1792145890469,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["E105"],"award-info":[{"award-number":["E105"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.cbi.2022.110042","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T04:29:49Z","timestamp":1657945789000},"page":"110042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions?"],"prefix":"10.1016","volume":"364","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-4488","authenticated-orcid":false,"given":"Estela","family":"Sang\u00fcesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Cirujeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Concha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Pablo","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-3483","authenticated-orcid":false,"given":"Cristina Bel\u00e9n","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Pilar","family":"Ribate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2022.110042_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatr."},{"issue":"2","key":"10.1016\/j.cbi.2022.110042_bib2","doi-asserted-by":"crossref","DOI":"10.4172\/2472-1077.1000109","article-title":"Bipolar disorders and valproate: pharmacokinetics,Pharmacodynamics, therapeutic effects and indications of valproate: review of articles","volume":"2","author":"Ayano","year":"2016","journal-title":"Bipolar Disord. Open Access"},{"key":"10.1016\/j.cbi.2022.110042_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004028.pub4","article-title":"Valproate for schizophrenia","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cbi.2022.110042_bib4","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.4088\/JCP.16r10782","article-title":"Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials","volume":"78","author":"Zheng","year":"2017","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.cbi.2022.110042_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2017.08.041","article-title":"Sodium valproate and clozapine induced neutropenia: a case control study using register data","volume":"195","author":"Malik","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.cbi.2022.110042_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/2050313X211019791","article-title":"Clozapine-associated neutropenia following augmentation with sodium valproate","volume":"9","author":"Jakobsen","year":"2021","journal-title":"SAGE Open Med. Case Reports"},{"key":"10.1016\/j.cbi.2022.110042_bib7","author":"Jackson"},{"key":"10.1016\/j.cbi.2022.110042_bib8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/15622975.2018.1439595","article-title":"TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians","volume":"19","author":"Schoretsanitis","year":"2018","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.cbi.2022.110042_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FPC.0000000000000347","article-title":"PharmGKB summary: clozapine pathway, pharmacokinetics","volume":"28","author":"Thorn","year":"2018","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.cbi.2022.110042_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","article-title":"ABCB1 and Cytochrome P450 Polymorphisms: clinical pharmacogenetics of clozapine","volume":"29","author":"Sirot","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2022.110042_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FPC.0b013e328354026b","article-title":"Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms","volume":"22","author":"Erickson-Ridout","year":"2012","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.cbi.2022.110042_bib12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.cbi.2022.110042_bib13","article-title":"Pharmacotherapy of the epilepsies. Goodman & gilman\u2019s: the pharmacological basis of therapeutics","author":"McNamara","year":"2018","journal-title":"McGraw Hill Medical"},{"key":"10.1016\/j.cbi.2022.110042_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00007691-199202000-00009","article-title":"Binding parameters of valproic acid to serum protein in healthy adults at steady state","volume":"14","author":"Kodama","year":"1992","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cbi.2022.110042_bib15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/phar.1965","article-title":"Clinical importance of monitoring unbound valproic acid concentration in patients with hypoalbuminemia","volume":"37","author":"Dor\u00e9","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cbi.2022.110042_bib16","first-page":"649","article-title":"Valproic acid: a simple method for the estimation of free serum concentration","volume":"51","author":"Parent","year":"1993","journal-title":"Ann. Biol. Clin."},{"key":"10.1016\/j.cbi.2022.110042_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1254\/jphs.FPE04007X","article-title":"A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients","volume":"97","author":"Hermida","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.cbi.2022.110042_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/ajp.151.1.123","article-title":"Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate","volume":"151","author":"Centorrino","year":"1994","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.cbi.2022.110042_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00007691-199906000-00017","article-title":"Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders","volume":"21","author":"Facciol\u00e0","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cbi.2022.110042_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5414\/CPP41003","article-title":"Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data","volume":"41","author":"Ulrich","year":"2003","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"10.1016\/j.cbi.2022.110042_bib21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/FTD.0000000000000513","article-title":"Effect of valproate and antidepressant drugs on clozapine metabolism in patients with psychotic mood disorders","volume":"40","author":"Marazziti","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cbi.2022.110042_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pnpbp.2005.10.008","article-title":"Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients","volume":"30","author":"Oi-Yin Wong","year":"2006","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.cbi.2022.110042_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/YIC.0b013e32835ac9da","article-title":"Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia","volume":"28","author":"Rajkumar","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2022.110042_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0006-3223(94)90647-5","article-title":"Potential impact of valproic acid therapy on clozapine disposition","volume":"36","author":"Finley","year":"1994","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.cbi.2022.110042_bib25","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1176\/ajp.152.4.650a","article-title":"Valproic acid effects on serum concentrations of clozapine and norclozapine","volume":"152","author":"Longo","year":"1995","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.cbi.2022.110042_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-2000-8355","article-title":"A case of pharmacokinetic interference in comedication of clozapine and valproic acid","volume":"33","author":"Conca","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.cbi.2022.110042_bib27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/JCP.0b013e3182a4ea8f","article-title":"A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism","volume":"33","author":"Riesselman","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2022.110042_bib28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JCP.0000000000000877","article-title":"Comedication of valproic acid is associated with increased metabolism of clozapine","volume":"38","author":"Hommers","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2022.110042_bib29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/FTD.0000000000000619","article-title":"Reduction in N -Desmethylclozapine level is determined by daily dose but not serum concentration of valproic acid - indications of a presystemic interaction mechanism","volume":"41","author":"Smith","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cbi.2022.110042_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/JCP.0000000000001507","article-title":"Effect of valproic acid on the metabolic spectrum of clozapine in patients with schizophrenia","volume":"42","author":"Smith","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2022.110042_bib31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1176\/appi.ajp.2019.18050589","article-title":"Pharmacogenomic variants and drug interactions identified through the genetic analysis of clozapine metabolism","volume":"176","author":"Pardi\u00f1as","year":"2019","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.cbi.2022.110042_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/pme-2021-0029","article-title":"Exploring the usefulness of plasma level determination and pharmacogenetics for patients treated with clozapine","volume":"19","author":"Sang\u00fcesa","year":"2022","journal-title":"Per. Med."},{"key":"10.1016\/j.cbi.2022.110042_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1600-0773.1998.tb01401.x","article-title":"Effect of cigarette smoke on UDP-glucuronosyltransferase activity and cytochrome P450 content in liver, lung and kidney microsomes in mice","volume":"82","author":"Villard","year":"1998","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.cbi.2022.110042_bib34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-199936060-00004","article-title":"Drug interactions with tobacco smoking. An update","volume":"36","author":"Zevin","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cbi.2022.110042_bib35","author":"Medicines Agency"},{"key":"10.1016\/j.cbi.2022.110042_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.cbi.2022.110042_bib37","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update, Ther","volume":"40","author":"Patsalos","year":"2018","journal-title":"Drug Monit"},{"key":"10.1016\/j.cbi.2022.110042_bib38","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.cbi.2022.110042_bib39","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","year":"2002","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.cbi.2022.110042_bib40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2022.110042_bib41","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2147\/NDT.S163839","article-title":"Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations","volume":"14","author":"Mayerova","year":"2018","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.cbi.2022.110042_bib42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004591","article-title":"Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables","volume":"41","author":"Diaz","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.cbi.2022.110042_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.pbb.2012.04.002","article-title":"In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes, Pharmacol","volume":"102","author":"Schmitt","year":"2012","journal-title":"Biochem. Behav."},{"key":"10.1016\/j.cbi.2022.110042_bib44","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/jpet.103.054197","article-title":"Interaction of antiepileptic drugs with human P-glycoprotein in vitro","volume":"307","author":"Weiss","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2022.110042_bib45","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2022.110042_bib46","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2217\/pgs.09.51","article-title":"ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients","volume":"10","author":"Consoli","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cbi.2022.110042_bib47","first-page":"235","article-title":"ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine","volume":"10","author":"Piatkov","year":"2017","journal-title":"Pharmgenomics. Pers. Med."},{"key":"10.1016\/j.cbi.2022.110042_bib48","first-page":"13","article-title":"Perspectives in clinical Polymorphisms in human MDR1 (P-glycoprotein)","volume":"1","author":"Marzolini","year":"2004","journal-title":"Recent advances and clinical relevance"},{"key":"10.1016\/j.cbi.2022.110042_bib49","unstructured":"DEPAKENE (valproic acid) Label. Enhanced Reader, https:\/\/www.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2016%2F018081s065_018082s048lbl.pdf (accessed 15 May 2022)."},{"key":"10.1016\/j.cbi.2022.110042_bib50","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","article-title":"Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007","volume":"32","author":"Couchman","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cbi.2022.110042_bib51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1590\/1516-4446-2012-0970","article-title":"Pharmacogenetics in schizophrenia: a review of clozapine studies","volume":"35","author":"Kohlrausch","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.cbi.2022.110042_bib52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.psychres.2013.02.030","article-title":"The CYP1A2 \u2013163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients","volume":"209","author":"Kohlrausch","year":"2013","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.cbi.2022.110042_bib53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/clpt.2011.70","article-title":"Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility","volume":"90","author":"Dobrinas","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2022.110042_bib54","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/FPC.0b013e328348c76b","article-title":"Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants","volume":"21","author":"Erickson-Ridout","year":"2011","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.cbi.2022.110042_bib55","first-page":"706","article-title":"The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among european americans, Pharmacogenet","volume":"23","author":"Bloom","year":"2013","journal-title":"Genomics"},{"key":"10.1016\/j.cbi.2022.110042_bib56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FPC.0000000000000269","article-title":"Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans","volume":"27","author":"Taghavi","year":"2017","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.cbi.2022.110042_bib59","first-page":"136","article-title":"Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproic acid auto-induction metabolism","volume":"44","author":"Lana","year":"2016","journal-title":"Actas Esp. Psiquiatr."},{"key":"10.1016\/j.cbi.2022.110042_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116534","article-title":"The proteomic and genomic teratogenicity elicited by valproic acid is preventable with resveratrol and \u03b1-tocopherol","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2022.110042_bib61","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0887-8994(03)00310-2","article-title":"Hypoalbuminemia with valproic acid administration","volume":"29","author":"Rugino","year":"2003","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.cbi.2022.110042_bib62","first-page":"99","article-title":"Valproic acid-associated hypoalbuminemia in medically fragile pediatric and young adult patients in a long term care facility: potential mechanisms for decreased albumin synthesis","volume":"16","author":"Blackford","year":"2012","journal-title":"Curr. Top. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110042_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.658734","article-title":"Clozapine metabolism is associated with absolute neutrophil count in individuals with treatment-resistant schizophrenia","volume":"12","author":"Willcocks","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110042_bib64","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FTD.0000000000000705","volume":"42","author":"de Leon","year":"2020","journal-title":"Ther. Drug Monit."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279722002472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279722002472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:07:48Z","timestamp":1757858868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279722002472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":62,"alternative-id":["S0009279722002472"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2022.110042","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions?","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2022.110042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110042"}}